Fish Oil / Omega-3 vs Inositol
Both are commonly discussed for mood. Fish Oil / Omega-3 has the stronger research base (moderate evidence), while Inositol is rated weak.
Evidence last reviewed May 2026
Fish Oil / Omega-3
Essential Fatty Acid
Inositol
Carbocyclic Sugar
Evidence
🟡Moderate Evidence
🟠Weak Evidence
Research says
Partially supported
Research agrees
Expert mentions
181
4 recommend
96
1 recommend
Studies
20
referenced
20
referenced
Study dose
1000–4000mg
Studies across the reviewed literature examined doses ranging from approximately 1,000 mg to 4,000 mg of combined EPA+DHA per day; expert commentary (Huberman) highlights doses above 1 g EPA/day for mood effects and 2–4 g/day for triglyceride reduction, though optimal doses vary by condition and individual.
2000–18000mg
Doses in PCOS and gestational diabetes research typically range from 2,000–4,000 mg/day of myo-inositol, while psychiatric studies (OCD, panic disorder, bipolar) have used up to 18,000 mg/day in divided doses; the D-chiro-inositol form is studied at much lower doses and the optimal myo- to D-chiro ratio (e.g., 40:1) varies by indication.
Best timing
MorningWith food
MorningEveningWith food
Who recommends
Caution
Generally safe
Generally safe
Fish Oil / Omega-3
Key findings
- ·Multiple strong-quality meta-analyses and systematic reviews suggest fish oil supplementation may improve blood lipid profiles (particularly triglycerides) in people with hyperlipidemia, and may reduce arterial stiffness based on randomized controlled trial data.
- ·Omega-3 supplementation has been investigated for PCOS, with systematic reviews and umbrella reviews of meta-analyses examining effects on metabolic and endocrine outcomes, though the strength and consistency of benefit varies across endpoints.
- ·A Mediterranean-style dietary intervention supplemented with fish oil showed promising signals for mental health improvement in people with depression, though this was a single moderate-quality RCT and conclusions should be drawn cautiously.
Evidence gaps
- ·Most individual studies in this set do not report specific population characteristics or sample sizes in the available metadata, making it difficult to determine which populations benefit most and whether findings generalize broadly.
- ·The majority of expert claims assessed (135 out of 169) were rated as having insufficient evidence, suggesting that many specific claims made about fish oil — including highly specific therapeutic applications — outpace what the current research can confidently support.
Inositol
Key findings
- ·Multiple meta-analyses support myo-inositol (typically 2–4 g/day) for improving metabolic and hormonal parameters in women with PCOS, representing the strongest evidence base for this supplement.
- ·Two meta-analyses of randomized controlled trials indicate that myo-inositol supplementation during pregnancy may reduce the incidence of gestational diabetes mellitus.
- ·Systematic reviews and network meta-analyses suggest inositol may provide modest benefit in Hashimoto's thyroiditis and subclinical hypothyroidism, though evidence is less definitive.
Evidence gaps
- ·Long-term safety and efficacy data are lacking across most indications — most trials are short-duration and do not establish whether benefits persist or whether adverse effects emerge with extended use.
- ·The optimal dose, form (myo-inositol vs. D-chiro-inositol vs. combined), and ratio for specific conditions have not been established through rigorous head-to-head dose-comparison trials.